NASDAQ:FLXN
Delisted
Flexion Therapeutics Stock News
$9.12
+0 (+0%)
At Close: May 27, 2022
U.S. RESEARCH ROUNDUP-Becton Dickinson, Epam Systems, PayPal Holdings
11:36am, Friday, 08'th May 2020
Wall Street securities analysts on Friday revised their ratings and price targets on several
U.S.-listed companies, including Becton Dickinson, Epam Systems and PayPal Holdings.
HIGHLIGHTS
Flexion Therapeutics Q1 EPS $(0.950) Beats $(0.990) Estimate, Sales $20.127M Beat $19.800M Estimate
09:51pm, Thursday, 07'th May 2020Flexion Therapeutics Reports First-Quarter 2020 Financial Results and Recent Business Highlights
08:01pm, Thursday, 07'th May 2020
Flexion Therapeutics, Inc. (FLXN) today reported financial results and recent business highlights for the quarter ended March 31, 2020. “We were very pleased with ZILRETTA’s trajectory earlier in
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
12:00am, Thursday, 07'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
Flexion Therapeutics, Inc. (FLXN) will present positive data from two studies of FX201, an investigational gene therapy for osteoarthritis (OA), at the American Society of Gene and Cell Therapy (ASGCT
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
Flexion Therapeutics (NASDAQ:FLXN) Stock Price Down 9.8% on Analyst Downgrade
06:56am, Saturday, 02'nd May 2020
Flexion Therapeutics Inc (NASDAQ:FLXN) fell 9.8% during trading on Friday after Needham & Company LLC lowered their price target on the stock from $36.00 to $30.00. Needham & Company LLC currently has
Flexion Therapeutics Announces Publication of New Abstracts Accepted at Osteoarthritis Research Society International OARSI 2020
01:00pm, Friday, 01'st May 2020
Flexion Therapeutics, Inc. (FLXN) today announced the publication of data from two new analyses of patients treated with ZILRETTA (triamcinolone acetonide injectable suspension), including an analysis
Northland Securities Remains a Buy on Opiant Pharmaceuticals (OPNT)
11:00am, Friday, 01'st May 2020
In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Opiant Pharmaceuticals (OPNT), with a price target of $42.00.
Northland Securities Remains a Buy on Opiant Pharmaceuticals (OPNT)
11:00am, Friday, 01'st May 2020
In a report released today,
Carl Byrnes
from Northland Securities maintained a
Buy
rating on Opiant Pharmaceuticals (
OPNT
–
Research Report
), with a price target of
$42.00
. The company’s shares
Flexion Therapeutics Announces Publication of New Abstracts Accepted at Osteoarthritis Research ...
12:00am, Friday, 01'st May 2020Flexion Therapeutics to Report First-Quarter 2020 Financial Results on May 7, 2020
08:30pm, Thursday, 30'th Apr 2020
Flexion Therapeutics, Inc. (FLXN) today announced that it will report its first-quarter 2020 financial results after the close of the U.S. financial markets on Thursday, May 7, 2020. The Company's co
Needham Maintains Buy on Flexion Therapeutics, Lowers Price Target to $30
12:36pm, Thursday, 30'th Apr 2020Flexion Therapeutics (NASDAQ:FLXN) PT Lowered to $20.00 at Raymond James
09:58am, Thursday, 30'th Apr 2020
Flexion Therapeutics (NASDAQ:FLXN) had its price objective reduced by Raymond James from $23.00 to $20.00 in a report published on Monday morning, AnalystRatings.com reports. Raymond James currently h
